Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis vaccines CMO joins Arterial

Dr Markus Weissbach becomes clinical trials director

Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its board.

Dr Weissback brings over 25 years of life science industry experience to the post - with particular expertise in cardiology, infectious diseases and oncology - and is currently chief operating officer at DS Biopharma in Dublin.

He recently served as chief medical officer at Novartis Vaccines and Diagnostics, and chief executive officer of Averion International.

Prior to this Weissbach was a director at Takeda Europe, with responsibility for its clinical research and development unit. He also brings expertise from Knoll, CytoTools Biotech, Vasopharm, Cardiorentis, BernaBiotech and Sunesis.

David Evans, director of Arterial, said: “The ability to convert strong science and supporting data into strong investor returns is what makes an outstanding private equity business.

“The addition of Markus to our team is fantastic news for investors and investees alike.”

21st February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...